Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
XNCR Stock Summary
Top 10 Correlated ETFs
XNCR
In the News
Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.36. This compares to loss of $0.20 per share a year ago.
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results, provide a.
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor (XNCR) Upgraded to Buy: What Does It Mean for the Stock?
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Xencor: Data In Early 2024 Could Bring Shareholder Value
Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers, which could generate shareholder value. The global metastatic castration-resistant prostate cancer treatment market is expected to reach $17.71 billion by 2029. Xencor is also planning to evaluate vudalimab in combination with chemotherapy for the treatment of patients with non-small cell lung cancer; the Study is expected to start before the end of 2023.
Xencor: A Mid-Stage Clinical Company With Falling Losses
Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and licensing agreements for approved molecules in hematologic cancers and blood disorders. Xencor's pipeline includes promising drugs like vudalimab, a bispecific antibody, but timing and toxicity concerns may impact their valuation.
Xencor to Present Multiple Posters at the SITC Annual Meeting
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced three poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in San Diego, November 1-5, 2023. Poster Presentation Details Clinical Trials in Progress Abstract 764, “A Phase 1, first-in-human (FIH), open-label, dose-findin.
Xencor, Inc. (XNCR) Q2 2023 Earnings Call Transcript
Xencor, Inc. (NASDAQ:XNCR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Charles Liles - Head of Corporate Communications & IR Bassil Dahiyat - Co-Founder and CEO Nancy Valente - Chief Development Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Mara Goldstein - Mizuho Securities Etzer Darout - BMO Capital Markets Edward Tenthoff - Piper Sandler Brian Chang - JPMorgan Alec Stranahan - Bank of America Merrill Lynch Kaveri Pohlman - BTIG Charles Zhu - Guggenheim Securities Matt Kemper - Leerink Partners Boris Peaker - TD Cowen Anish Nikhanj - RBC Capital Markets Operator Good afternoon, and thank you for standing by. Welcome to Xencor's Second Quarter 2023 Conference Call.
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.57 per share a year ago.
XNCR Financial details
XNCR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.77 | 2.14 | 4.71 | 2.77 | 2.78 | |
Net income per share | 0.48 | -1.11 | 1.42 | -0.93 | -2.08 | |
Operating cash flow per share | 1.14 | -0.09 | -0.29 | 0.41 | 1.41 | |
Free cash flow per share | 0.94 | -0.33 | -0.56 | -0.32 | 1.06 | |
Cash per share | 9.37 | 10.54 | 5.72 | 10.5 | 9.81 | |
Book value per share | 10.49 | 10.01 | 12.56 | 12.26 | 11.05 | |
Tangible book value per share | 10.24 | 9.73 | 12.28 | 11.95 | 10.75 | |
Share holders equity per share | 10.49 | 10.01 | 12.56 | 12.26 | 11.05 | |
Interest debt per share | 0.19 | 0.2 | 0.58 | 0.39 | 0.4 | |
Market cap | 1.94B | 2.5B | 2.34B | 1.55B | 1.28B | |
Enterprise value | 1.9B | 2.34B | 2.23B | 1.55B | 1.31B | |
P/E ratio | 72.34 | -39.29 | 28.35 | -28 | -10.19 | |
Price to sales ratio | 12.41 | 20.34 | 8.51 | 9.39 | 7.63 | |
POCF ratio | 30.2 | -498.84 | -138.98 | 63.1 | 15.09 | |
PFCF ratio | 36.45 | -132.97 | -71.33 | -81.67 | 20.11 | |
P/B Ratio | 3.28 | 4.36 | 3.19 | 2.12 | 1.92 | |
PTB ratio | 3.28 | 4.36 | 3.19 | 2.12 | 1.92 | |
EV to sales | 12.15 | 19.11 | 8.12 | 9.42 | 7.81 | |
Enterprise value over EBITDA | 137.77 | -30.53 | 51.01 | -18.8 | -10.34 | |
EV to operating cash flow | 29.59 | -468.48 | -132.48 | 63.34 | 15.44 | |
EV to free cash flow | 35.71 | -124.88 | -68 | -81.97 | 20.58 | |
Earnings yield | 0.01 | -0.03 | 0.04 | -0.04 | -0.1 | |
Free cash flow yield | 0.03 | -0.01 | -0.01 | -0.01 | 0.05 | |
Debt to equity | 0.02 | 0.02 | 0.05 | 0.08 | 0.04 | |
Debt to assets | 0.02 | 0.02 | 0.04 | 0.07 | 0.03 | |
Net debt to EBITDA | -2.86 | 1.98 | -2.5 | -0.07 | -0.23 | |
Current ratio | 8.39 | 5.27 | 6 | 10.58 | 7.36 | |
Interest coverage | 0 | 0 | 0 | 2.24 | 0 | |
Income quality | 2.4 | 0.07 | -0.2 | -0.44 | -0.68 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.15 | 0.24 | 0.14 | 0.29 | 0.32 | |
Research and developement to revenue | 0.76 | 1.38 | 0.7 | 1.21 | 1.51 | |
Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Capex to operating cash flow | -0.17 | 2.75 | 0.95 | -1.77 | -0.25 | |
Capex to revenue | -0.07 | -0.11 | -0.06 | -0.26 | -0.13 | |
Capex to depreciation | -2.57 | -2.38 | -2.13 | -4.93 | -1.85 | |
Stock based compensation to revenue | 0.2 | 0.26 | 0.13 | 0.3 | 0.32 | |
Graham number | 10.59 | 15.81 | 20 | 16.02 | 22.77 | |
ROIC | 0.02 | -0.12 | 0.06 | -0.1 | -0.19 | |
Return on tangible assets | 0.04 | -0.09 | 0.1 | -0.07 | -0.13 | |
Graham Net | 8.3 | 8.57 | 4.47 | 8.87 | 5.17 | |
Working capital | 491.85M | 516.61M | 353.63M | 611.5M | 538.45M | |
Tangible asset value | 578.78M | 556.47M | 717.01M | 709M | 650.47M | |
Net current asset value | 481.36M | 506.87M | 319.66M | 556.57M | 339.6M | |
Invested capital | 0.02 | 0.02 | 0.05 | 0.08 | 0.04 | |
Average receivables | 16.53M | 23.01M | 45.16M | 47.69M | 20.14M | |
Average payables | 6.99M | 9.57M | 11.48M | 12.04M | 12M | |
Average inventory | 0.5 | 0.5 | -18.43M | -18.43M | -5.64M | |
Days sales outstanding | 51.42 | 71.23 | 88.07 | 64.31 | 24.48 | |
Days payables outstanding | 31.36 | 19.25 | 682.2 | 418.47 | 441.7 | |
Days of inventory on hand | 0 | 0 | -1.8K | 0 | -358.4 | |
Receivables turnover | 7.1 | 5.12 | 4.14 | 5.68 | 14.91 | |
Payables turnover | 11.64 | 18.96 | 0.54 | 0.87 | 0.83 | |
Inventory turnover | 118.59M | 0 | -0.2 | 8.8M | -1.02 | |
ROE | 0.05 | -0.11 | 0.11 | -0.08 | -0.19 | |
Capex per share | -0.2 | -0.24 | -0.27 | -0.73 | -0.35 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.38 | 0.32 | 0.77 | 0.98 | 0.73 | |
Net income per share | -0.21 | -1.01 | -0.37 | -0.4 | -0.31 | |
Operating cash flow per share | -0.43 | -0.51 | -0.64 | -0.45 | 2.98 | |
Free cash flow per share | -0.62 | -0.7 | -0.73 | -0.51 | 2.95 | |
Cash per share | 10.87 | 9.87 | 9.29 | 8.16 | 9.76 | |
Book value per share | 12.7 | 11.47 | 11.44 | 11.04 | 10.99 | |
Tangible book value per share | 12.37 | 11.17 | 11.13 | 10.73 | 10.69 | |
Share holders equity per share | 12.7 | 11.47 | 11.44 | 11.04 | 10.99 | |
Interest debt per share | 0.99 | 0.98 | 0.99 | 1 | 0.4 | |
Market cap | 1.49B | 1.66B | 1.48B | 1.22B | 1.29B | |
Enterprise value | 1.5B | 1.65B | 1.51B | 1.23B | 1.32B | |
P/E ratio | -30.98 | -6.93 | -16.87 | -12.58 | -16.91 | |
Price to sales ratio | 69.05 | 87.62 | 32.55 | 20.65 | 28.91 | |
POCF ratio | -61.08 | -54.27 | -38.79 | -44.78 | 7.13 | |
PFCF ratio | -42.24 | -39.74 | -34.35 | -39.79 | 7.2 | |
P/B Ratio | 2.05 | 2.43 | 2.18 | 1.83 | 1.93 | |
PTB ratio | 2.05 | 2.43 | 2.18 | 1.83 | 1.93 | |
EV to sales | 69.32 | 86.93 | 33.08 | 20.78 | 29.57 | |
Enterprise value over EBITDA | -35.17 | -27.77 | -57.92 | -67.31 | -43.47 | |
EV to operating cash flow | -61.31 | -53.84 | -39.42 | -45.07 | 7.29 | |
EV to free cash flow | -42.4 | -39.43 | -34.91 | -40.05 | 7.36 | |
Earnings yield | -0.01 | -0.04 | -0.01 | -0.02 | -0.01 | |
Free cash flow yield | -0.02 | -0.03 | -0.03 | -0.03 | 0.14 | |
Debt to equity | 0.08 | 0.09 | 0.09 | 0.09 | 0.04 | |
Debt to assets | 0.07 | 0.07 | 0.08 | 0.08 | 0.03 | |
Net debt to EBITDA | -0.13 | 0.22 | -0.93 | -0.44 | -0.98 | |
Current ratio | 10.58 | 9.68 | 13.3 | 10.77 | 7.36 | |
Interest coverage | 15.49 | 70.09 | 0 | 0 | 0 | |
Income quality | 2.03 | 0.5 | 1.74 | 1.12 | -9.49 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.59 | 0.74 | 0.25 | 0.21 | 0.35 | |
Research and developement to revenue | 2.38 | 3.4 | 1.32 | 1.1 | 1.41 | |
Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Capex to operating cash flow | 0.45 | 0.37 | 0.13 | 0.13 | -0.01 | |
Capex to revenue | -0.5 | -0.59 | -0.11 | -0.06 | -0.04 | |
Capex to depreciation | -5.05 | -4.98 | -1.71 | -1.09 | -0.53 | |
Stock based compensation to revenue | 0.59 | 0.66 | 0.3 | 0.22 | 0.33 | |
Graham number | 7.75 | 16.11 | 9.76 | 9.97 | 8.81 | |
ROIC | -0.05 | -0.07 | -0.03 | -0.02 | -0.06 | |
Return on tangible assets | -0.01 | -0.08 | -0.03 | -0.03 | -0.02 | |
Graham Net | 9.18 | 8.11 | 7.87 | 7.03 | 5.24 | |
Working capital | 611.5M | 564.92M | 548.93M | 518.14M | 538.45M | |
Tangible asset value | 709M | 665.34M | 660.17M | 650.27M | 650.47M | |
Net current asset value | 556.57M | 510.15M | 494.32M | 461.76M | 339.6M | |
Invested capital | 0.08 | 0.09 | 0.09 | 0.09 | 0.04 | |
Average receivables | 36.94M | 24.43M | 19.94M | 37.51M | 33.15M | |
Average payables | 12.35M | 12.71M | 14.72M | 14.53M | 14.44M | |
Average inventory | 0.5 | 1 | 1 | 0.5 | 0 | |
Days sales outstanding | 120.76 | 94.27 | 39.58 | 83.67 | 22.74 | |
Days payables outstanding | 420.53 | 615.01 | 439.77 | 428.99 | 387.94 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.75 | 0.95 | 2.27 | 1.08 | 3.96 | |
Payables turnover | 0.21 | 0.15 | 0.2 | 0.21 | 0.23 | |
Inventory turnover | 2.16M | 2.25M | 2.89M | 0 | 0 | |
ROE | -0.02 | -0.09 | -0.03 | -0.04 | -0.03 | |
Capex per share | -0.19 | -0.19 | -0.08 | -0.06 | -0.03 |
XNCR Frequently Asked Questions
What is Xencor, Inc. stock symbol ?
Xencor, Inc. is a US stock , located in Monrovia of Ca and trading under the symbol XNCR
Is Xencor, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $56. The lowest prediction is $54 and the highest is $58
What is XNCR stock prediction ?
What is Xencor, Inc. stock quote today ?
Xencor, Inc. stock price is $22.13 today.
Is Xencor, Inc. stock public?
Yes, Xencor, Inc. is a publicly traded company.